Volume 21, Issue 1 (4-2018)
Hakim 2018, 21(1): 50-56 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Jafari M, Lotfi F, Kojuri J, Behnam Morshedi H, Keshavarz K. An Estimation of Costs of Intracoronary/Intramyocardial Injection Technology of Patient Bone Marrow Cell (BMC) Affiliated to Heart Failure in Comparison with Common Treatment Methods in Iran. Hakim 2018; 21 (1) :50-56
URL: http://hakim.tums.ac.ir/article-1-1857-en.html
URL: http://hakim.tums.ac.ir/article-1-1857-en.html
1- , khkeshavarz2007@gmail.com
Abstract: (3826 Views)
An Estimation of Costs of Intracoronary/Intramyocardial Injection Technology of Patient Bone Marrow Cell (BMC) Affiliated to Heart Failure in Comparison with Common Treatment Methods in Iran
Mojtaba Jafari (BSc)1; Farhad Lotfi (PhD)1; Javad Kojuri (MD)2; Hossein Behnam Morshedi (BSc)1, Khosro Keshavarz (PhD)1*
1Health Human Resources Research Center, Department of Health Economics, School of Management and
Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
2Quality Improvement in Clinical Education Research Center,
Shiraz University of Medical Sciences, Shiraz, Iran
Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
2Quality Improvement in Clinical Education Research Center,
Shiraz University of Medical Sciences, Shiraz, Iran
Abstract
Introduction: Heart failure is a chronic disease that is one of the most important causes in the world. This subject puts large costs on society. The object of this study is the estimation of direct medical cost on injection technology of patient bone marrow cell affiliated to heart failure in comparison with common treatment methods in Iran.
Methods: In order to estimate treatment cost of injection technology of patient bone marrow cell affiliated to heart failure in comparison with common treatment methods, only direct medical costs were considered. The study perspective was ministry of health and providers. Costs were calculated with Excel software based on private and public tariff.
Results: In 2016, treatment cost per capita based on public and private tariff were respectively 120 and 222 million IR Rial for bone morrow cell, 122 and 218 IR Rial for CRT, 120 and 214 for peace maker, 68 and 140 for pharmacotherapy in a one-year period, and also 138 and 233 million IR Rial for IABP in a 10 day period. Therefore, the treatment cost based on private tariff is almost among 1.7 to 2 time’s public tariff. In addition, in terms of cost, pharmacotherapy had the least and IABP had the most.
Conclusions: In general, the result showed that the cost of bone marrow cell had no significant difference with other treatment methods and the costs were almost similar. Therefore, it’s proposed that to enter this technology, we must notice to the effectiveness aspect and the cost effectiveness analysis must be done.
Keywords: Heart Failure; Bone Marrow Cell; Direct Medical Cost
Introduction: Heart failure is a chronic disease that is one of the most important causes in the world. This subject puts large costs on society. The object of this study is the estimation of direct medical cost on injection technology of patient bone marrow cell affiliated to heart failure in comparison with common treatment methods in Iran.
Methods: In order to estimate treatment cost of injection technology of patient bone marrow cell affiliated to heart failure in comparison with common treatment methods, only direct medical costs were considered. The study perspective was ministry of health and providers. Costs were calculated with Excel software based on private and public tariff.
Results: In 2016, treatment cost per capita based on public and private tariff were respectively 120 and 222 million IR Rial for bone morrow cell, 122 and 218 IR Rial for CRT, 120 and 214 for peace maker, 68 and 140 for pharmacotherapy in a one-year period, and also 138 and 233 million IR Rial for IABP in a 10 day period. Therefore, the treatment cost based on private tariff is almost among 1.7 to 2 time’s public tariff. In addition, in terms of cost, pharmacotherapy had the least and IABP had the most.
Conclusions: In general, the result showed that the cost of bone marrow cell had no significant difference with other treatment methods and the costs were almost similar. Therefore, it’s proposed that to enter this technology, we must notice to the effectiveness aspect and the cost effectiveness analysis must be done.
Keywords: Heart Failure; Bone Marrow Cell; Direct Medical Cost
Please cite this article as follows:
Jafari M; Lotfi F; Kojuri J; Behnam Morshedi H; Keshavarz Kh. An Estimation of Costs of Intracoronary/Intramyocardial Injection Technology of Patient Bone Marrow Cell (BMC) Affiliated to Heart Failure in Comparison with Common Treatment Methods in Iran. Hakim Health Sys Res 2018; 21(1): 50- 56
*Corresponding Author: Health Human Resources Research Center, Department of Health Economics; School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran. Tel/Fax: +98-7132340039, E-mail: khkeshavarz2007@gmail.com
Type of Study: Original |
Subject:
General
Received: 2018/09/5 | Accepted: 2018/09/5 | Published: 2018/09/5
Received: 2018/09/5 | Accepted: 2018/09/5 | Published: 2018/09/5
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
